Fig. 3. Cardiomyocyte contractile properties in control and cardiac-specific Ctsk-CKO mice treated with or without doxorubicin.

a Resting cell length; b Peak shortening (PS), normalized to cell length; c Maximal velocity of shortening (+dL/dt); d Maximal velocity of relengthening (−dL/dt); e Time-to PS (TPS); f Time-to-90% relengthening (TR90). Mean ± SEM, n = 88–102 cells from three to four mice per group. *p < 0.05 vs. Control group, #p < 0.05 vs. Control-Dox group